SUPPLEMENTARY TABLE 2. Prespecified outcomes*,† for recombinant zoster vaccine (RZV) in reports submitted to the Vaccine Adverse Events Reporting System (VAERS) — United States, October 2017–June 2018
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All
i


SUPPLEMENTARY TABLE 2. Prespecified outcomes*,† for recombinant zoster vaccine (RZV) in reports submitted to the Vaccine Adverse Events Reporting System (VAERS) — United States, October 2017–June 2018

  • Published Date:

    February 28, 2019

  • Source:
    MMWR. Morbidity and mortality weekly report ; v. 68, no. 4
  • Language:
    English
Filetype[PDF-349.78 KB]


Details:
  • Supporting Files:
    No Additional Files

You May Also Like:

  1. Filetype[PDF - 265.31 KB]
    Published Date:
    February 28, 2019
    Source:
    MMWR. Morbidity and mortality weekly report ; v. 68, no. 4
    Description:
    Supplements: Post-licensure safety surveillance of recombinant zoster vaccine (Shingrix) —Vaccine Adverse Event Reporting System (VAERS), United Sta...
    File Type:
    Filetype[PDF - 265.31 KB]
    File Type:
    Filetype[PDF - 265.31 KB]
  2. Filetype[PDF - 466.12 KB]
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.) ; United States. Food and Drug Administration. ;
    Published Date:
    12/17/03
    Description:
    The Vaccine Adverse Event Reporting System (VAERS) is a national program that monitors the safety of vaccines after they are licensed. VAERS is manage...
    File Type:
    Filetype[PDF - 466.12 KB]
    File Type:
    Filetype[PDF - 466.12 KB]
  3. Filetype[PDF - 295.10 KB]
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.) ; United States. Food and Drug Administration. ; ...
    Published Date:
    February 2013
    Description:
    • The Vaccine Adverse Event Reporting System (VAERS) is one component of the United States’ comprehensive vaccine safety monitoring system.• VAE...
    File Type:
    Filetype[PDF - 295.10 KB]
    File Type:
    Filetype[PDF - 295.10 KB]
  4. Filetype[PDF - 14.12 KB]
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.) ; United States. Food and Drug Administration. ;
    Published Date:
    1/31/03
    File Type:
    Filetype[PDF - 14.12 KB]
    File Type:
    Filetype[PDF - 14.12 KB]
  5. Filetype[PDF - 263.85 KB]
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.) ; United States. Food and Drug Administration. ;
    Published Date:
    8/30/09
    Description:
    The Vaccine Adverse Event Reporting System (VAERS) is a national program that monitors the safety of vaccines after they are licensed. VAERS is manage...
    File Type:
    Filetype[PDF - 263.85 KB]
    File Type:
    Filetype[PDF - 263.85 KB]